CIK 0001740279
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
IN8BIO, INC.
Sign in to watch- Ticker
- INAB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825462585
- Phone
- +1 646-600-6438
- Business address
- EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
- Former names
- Incysus Therapeutics, Inc.
- 4 Grant or award President and CEO acquired 81,967 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 20,492 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 12,295 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 4,098 shares (grant or award)
- 4 Grant or award EVP and CSO acquired 1,639 shares (grant or award)
- 4 Grant or award Director acquired 81,967 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 2,500 shares at $0.95 ($2,375)
- 4 Open-market buy Chief Financial Officer bought 1,000 shares at $1.03 ($1,030)
- 4 Open-market buy President and CEO bought 23,800 shares at $1.05 ($24,990)
- 4 Other disposition Director disposed of 4,111,958 shares (other)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 5 of 10 · 185 filings